Levact

Bendamustine Hydrochloride, the active ingredient in Levact, is an alkylating agent (nitrogen mustard) presented as an intravenous solution for intravenous use. It is indicated for the treatment of chronic lymphocytic leukemia and non‑Hodgkin lymphoma in adult patients.

GNH USA supplies Levact as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Levact is an alkylating antineoplastic agent used in hematologic malignancies.

Chronic lymphocytic leukemia (CLL): improves disease control and prolongs survival in eligible patients. Non‑Hodgkin lymphoma (NHL): induces remission and extends progression‑free survival in appropriate disease subtypes. Mantle cell lymphoma (MCL): provides therapeutic benefit as part of combination regimens in adult patients.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness affecting daily activities. - Myelosuppression: neutropenia, anemia, and thrombocytopenia. - Fever: often associated with infection risk. - Alopecia: reversible hair loss. - Infections: increased susceptibility to bacterial, viral or fungal pathogens.

Serious or Rare Side Effects: - Severe infections: sepsis or opportunistic infections requiring hospitalization. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Secondary malignancies: rare development of new cancers. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac toxicity: arrhythmias or myocardial injury.

Careful monitoring and patient counseling are essential before and during therapy.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess organ function: evaluate renal and hepatic function prior to each cycle. Screen for infections: treat active infections before initiating treatment. Use contraception: advise both male and female patients to avoid pregnancy. Avoid hypersensitivity: discontinue if severe allergic reaction occurs. Store at controlled room temperature: keep in original container, protect from moisture and light.

Bendamustine may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase bendamustine exposure. - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Concurrent myelosuppressive agents: can exacerbate bone‑marrow toxicity. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness. - Hypersensitivity‑inducing agents: increase risk of severe allergic reactions.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): heightened bleeding risk. - Other chemotherapy drugs: overlapping toxicities require dose adjustments. - Immunosuppressants (e.g., tacrolimus): may augment infection risk. - Antacids containing aluminum or magnesium: could affect absorption of concomitant oral meds. - Herbal supplements (St. John’s wort): potential CYP3A4 induction.